Insights into the role of HCV Plus-/Minus strand RNA, IFN-γ and IL-29 in relapse outcome in patients infected with HCV

• Published in: Asian Pacific journal of allergy and immunology Vol. 33; no. 3; p. 173
• Main Authors: Alborzi, Amir Mohammad, Bamdad, Taravat, Davoodian, Parivash, Hashempoor, Tayebeh, Nejatizadeh, Abdol Azim, Moayedi, Javad
• Format: Journal Article
• Language: English
• Published: Thailand 01.09.2015
• Subjects: Adult; Aged; Antiviral Agents - therapeutic use; Biomarkers - blood; Female; Hepacivirus - drug effects; Hepacivirus - genetics; Hepacivirus - immunology; Hepatitis C - blood; Hepatitis C - drug therapy; Hepatitis C - immunology; Hepatitis C - virology; Host-Pathogen Interactions; Humans; Interferon-gamma - blood; Interleukins - blood; Leukocytes, Mononuclear - immunology; Leukocytes, Mononuclear - virology; Male; Middle Aged; Predictive Value of Tests; Recurrence; RNA, Viral - genetics; Time Factors; Treatment Failure

Approximately one-third of hepatitis C virus (HCV) infected patients who complete antiviral therapy with undetectable serum HCV RNA at the end of therapy (ETR), will experience relapse. The reasons for the failure of treatment have not been elucidated. It was showed that HCV RNA can persist and repl...